ATE321781T1 - Verfahren zur herstellung einer proteinhaltigen fraktion, mit beta-tgf in aktivierter form bereichert, sowie die so erhaltene fraktion und deren therapeutische verwendungen - Google Patents

Verfahren zur herstellung einer proteinhaltigen fraktion, mit beta-tgf in aktivierter form bereichert, sowie die so erhaltene fraktion und deren therapeutische verwendungen

Info

Publication number
ATE321781T1
ATE321781T1 AT02764984T AT02764984T ATE321781T1 AT E321781 T1 ATE321781 T1 AT E321781T1 AT 02764984 T AT02764984 T AT 02764984T AT 02764984 T AT02764984 T AT 02764984T AT E321781 T1 ATE321781 T1 AT E321781T1
Authority
AT
Austria
Prior art keywords
tgf
beta
fraction
solution
activated form
Prior art date
Application number
AT02764984T
Other languages
English (en)
Inventor
Jean-Louis Maubois
Jacques Fauquant
Pierre Jouan
Michel Bourtourault
Original Assignee
Pierre Jouan Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Jouan Biotechnologies Sa filed Critical Pierre Jouan Biotechnologies Sa
Application granted granted Critical
Publication of ATE321781T1 publication Critical patent/ATE321781T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02764984T 2001-07-13 2002-07-12 Verfahren zur herstellung einer proteinhaltigen fraktion, mit beta-tgf in aktivierter form bereichert, sowie die so erhaltene fraktion und deren therapeutische verwendungen ATE321781T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0109390A FR2827290B1 (fr) 2001-07-13 2001-07-13 Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques

Publications (1)

Publication Number Publication Date
ATE321781T1 true ATE321781T1 (de) 2006-04-15

Family

ID=8865500

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02764984T ATE321781T1 (de) 2001-07-13 2002-07-12 Verfahren zur herstellung einer proteinhaltigen fraktion, mit beta-tgf in aktivierter form bereichert, sowie die so erhaltene fraktion und deren therapeutische verwendungen

Country Status (13)

Country Link
US (3) US7141262B2 (de)
EP (1) EP1409539B1 (de)
JP (1) JP4688092B2 (de)
AT (1) ATE321781T1 (de)
AU (1) AU2002329364B8 (de)
CA (1) CA2434303C (de)
DE (1) DE60210304T2 (de)
DK (1) DK1409539T3 (de)
ES (1) ES2258154T3 (de)
FR (1) FR2827290B1 (de)
GB (1) GB0324873D0 (de)
NZ (1) NZ529180A (de)
WO (1) WO2003006500A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827290B1 (fr) * 2001-07-13 2004-07-09 Pierre Jouan Biotechnologies Sa Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
AU2003235874A1 (en) * 2003-05-07 2004-11-26 Snow Brand Milk Products Co., Ltd. Skin collagen production promoter
ES2314152T3 (es) * 2003-09-12 2009-03-16 Nestec S.A. Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de enfermedades inducidas por la cox-2.
EP2335650B1 (de) 2003-12-11 2012-10-03 Isto Technologies Inc. Teilchenförmiges Knorpelsystem
TW200533299A (en) * 2004-03-31 2005-10-16 Calpis Co Ltd Functional food for improving endogenous rhythm of melatonin secretion, and functional food for improving circadian rhythm
GB0423352D0 (en) * 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
EP1817347B1 (de) * 2004-11-24 2017-05-17 Albumedix A/S Verfahren zur vernetzung von hyaluronsäure mit divinylsulfon
EP1669086A1 (de) * 2004-12-09 2006-06-14 Advitech Solutions Inc. Zusammensetzung enthaltend TGF-beta und Proteine zur Behandlung von Schuppenflechte
US20060127493A1 (en) * 2004-12-09 2006-06-15 Yves Pouliot Composition for treating psoriasis
US7763257B2 (en) * 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) * 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
JP5292533B2 (ja) 2005-08-26 2013-09-18 ジンマー・インコーポレイテッド インプラントおよび関節疾患の治療、置換および治療方法
NZ567126A (en) * 2005-10-04 2010-09-30 Advitech Inc A dairy derived composition comprising beta-lactoglobulin, IGF and TGF-beta for use in treating chronic intestinal inflammatory disease
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20100119614A1 (en) * 2007-04-03 2010-05-13 Christina Juneau Process for the manufacture of a dairy-based anti-inflammatory composition
EP2134297B1 (de) 2007-04-12 2017-03-08 Zimmer, Inc. Vorrichtung zur gewebereparatur
US20080293159A1 (en) * 2007-05-24 2008-11-27 Murray Goulburn Co-Operative Co. Ltd. Validation Process
CA2687123A1 (en) * 2007-06-11 2008-12-18 Advitech Inc. Method for the treatment of atopic eczema
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
WO2010028432A1 (en) * 2008-09-11 2010-03-18 Healthlinx Limited Protocols for treating bone disorders
US8986769B2 (en) * 2008-10-24 2015-03-24 Mead Johnson Nutrition Company Methods for preserving endogenous TGF-β
US8367354B2 (en) * 2008-10-24 2013-02-05 Mead Johnson Nutrition Company Methods for determining the levels of TGF-β in a composition
US8350006B2 (en) * 2008-10-24 2013-01-08 Mead Johnson Nutrition Company Methods for determining the bioactivity of TGF-β in a composition
US9055752B2 (en) 2008-11-06 2015-06-16 Intercontinental Great Brands Llc Shelf-stable concentrated dairy liquids and methods of forming thereof
KR20120089725A (ko) * 2009-10-16 2012-08-13 우먼'스 앤드 칠드런'스 헬스 리서치 인스티튜트 산 처리 수성 유청 단백질 추출물을 사용하는 알레르기 치료 방법
UA112972C2 (uk) 2010-09-08 2016-11-25 Інтерконтінентал Грейт Брендс ЛЛС Рідкий молочний концентрат з високим вмістом сухих речовин
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
EP3247343A1 (de) * 2015-01-23 2017-11-29 Nestec S.A. Ernährungszusammensetzung zur behandlung von patienten mit entzündlichen darmerkrankungen
US10094030B2 (en) 2015-02-03 2018-10-09 Tipul Biotechnology, LLC Devices and methods for electrolytic production of disinfectant solution from salt solution in a container
EP3969019A4 (de) * 2019-05-14 2023-06-07 Hadasit Medical Research Services and Development Ltd. Von milch abgeleitete extrazelluläre vesikel zur verwendung bei der behandlung von entzündlichen darmerkrankungen
TWI751551B (zh) * 2020-05-11 2022-01-01 中化合成生技股份有限公司 一種將化合物溶液除水並進行共軛酸轉換之方法
FR3115037B1 (fr) * 2020-10-12 2025-02-21 Cie Laitiere Europeenne Procédé de purification de fraction de protéines cationiques et fraction ainsi obtenue
FR3159096A1 (fr) 2024-02-08 2025-08-15 Compagnie Laitiere Europeenne Utilisation de TGF-β pour la prévention et le traitement des manifestations névralgiques

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3791283A (en) * 1970-08-28 1974-02-12 Gen Foods Corp Method for producing heat and acid stable whey protein material
BE786588A (fr) * 1971-07-20 1973-01-22 Unilever Nv Compositions alimentaires
CH556143A (fr) * 1972-09-11 1974-11-29 Nestle Sa Procede de preparation d'une fraction soluble des proteines du petit lait.
US3883448A (en) * 1973-04-23 1975-05-13 Miles Lab Recovery and purification of protein
US3997447A (en) * 1974-06-07 1976-12-14 Composite Sciences, Inc. Fluid processing apparatus
US3992375A (en) * 1974-08-12 1976-11-16 G. D. Searle & Co. Dibenzoxazepine N-carboxylic acid hydrazines and derivatives
SE396017B (sv) * 1974-12-23 1977-09-05 Alfa Laval Ab Filtreringsforfarande, serskilt for ultrafiltrering
US4029825A (en) * 1975-05-30 1977-06-14 Stauffer Chemical Company Production of egg white substitute from whey
GB1591609A (en) * 1976-09-24 1981-06-24 Unilever Ltd Fat
DE3164983D1 (en) * 1980-04-17 1984-08-30 Bridel Laiteries Decationized milk, process for treating milk by a cation exchange resin for the manufacture of decationized milk and use of the decationized milk in the manufacture of curdled milk casein for cheeses and lactoserum
US4462989A (en) * 1981-05-04 1984-07-31 Evreka, Inc. Method and agents for arresting infection
US5017372A (en) * 1986-04-14 1991-05-21 Medicis Corporation Method of producing antibody-fortified dry whey
SE459715B (sv) * 1986-09-08 1989-07-31 Karl J Allsing Foerfarande vid s.k.roterande filter samt filter
SE459140B (sv) * 1986-11-25 1989-06-12 Albuglobe Ab Hydrolys av vassleprotein foer att underlaetta avskiljning av fett daerifraan
US5221734A (en) * 1987-10-01 1993-06-22 Ciba-Geigy Corporation Process for preparing a polypeptide growth factor for milk
GB8723094D0 (en) 1987-10-01 1987-11-04 Ciba Geigy Ag Polypeptide growth factor from milk
US5047249A (en) * 1988-07-22 1991-09-10 John Morris Co., Inc. Compositions and methods for treating skin conditions and promoting wound healing
US5043431A (en) * 1989-09-11 1991-08-27 Codon Method and apparatus for the production of TGF-β
US5037532A (en) * 1989-09-28 1991-08-06 Exxon Research & Engineering Company Slurry hydrotreating process
US5122536A (en) * 1989-10-12 1992-06-16 Perricone Nicholas V Method for the topical treatment of psoriasis
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
EP0527283B1 (de) 1991-08-12 1997-11-26 Societe Des Produits Nestle S.A. Nahrungsmittelzusammensetzung
CA2095057C (en) 1992-06-19 1998-06-16 Peter John Degen Production of sterile milk through dynamic microfiltration
US5256437A (en) * 1992-06-19 1993-10-26 Pall Corporation Product and process of making sterile milk through dynamic microfiltration
US5527350A (en) * 1993-02-24 1996-06-18 Star Medical Technologies, Inc. Pulsed infrared laser treatment of psoriasis
US6036979A (en) * 1993-11-29 2000-03-14 Van Den Bergh Foods Co., Division Of Conopco, Inc. Manufacture of spreadable low-fat cheese
JP3759984B2 (ja) * 1995-10-13 2006-03-29 よつ葉乳業株式会社 牛乳プロテオースペプトンのコンポーネント3の精製法
EP0894094B1 (de) * 1996-03-15 2005-05-11 BioEqual AG Verfahren zur gewinnung eines komplexes aus wachstumsfaktoren
EP1052013A1 (de) 1997-04-09 2000-11-15 Societe Des Ceramiques Techniques Makroporöser Träger mit einem Permeabilitätsgradient und Methode zu dessen Herstellung
US6139901A (en) * 1997-09-16 2000-10-31 New Zealand Milk Products (North Amerca) Inc. Membrane filtered milk proteins varying in composition and functional attributes
US6312755B1 (en) * 1999-07-16 2001-11-06 Ampc Whey treatment process for achieving high concentration of α-lactalbumin
WO2001025276A1 (en) * 1999-10-06 2001-04-12 Campina B.V. Process for obtaining growth factor preparations (tgf-beta and igf-1) from milk products having low mutual cross-contamination
AU6232899A (en) * 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
FR2827290B1 (fr) * 2001-07-13 2004-07-09 Pierre Jouan Biotechnologies Sa Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
ATE420108T1 (de) * 2001-07-20 2009-01-15 Campina Bv Verfahren zur herstellung von preparationen aus milchprodukten, welche wachstumsfaktoren (tgf- beta und igf-1), lactoperoxidase und immunglobuline mit niedriger gegenseitiger verunreinigung enthalten
US7763257B2 (en) * 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
FR2889068B1 (fr) 2005-07-29 2012-03-02 Cie Laitiere Europeenne Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques
NZ567126A (en) 2005-10-04 2010-09-30 Advitech Inc A dairy derived composition comprising beta-lactoglobulin, IGF and TGF-beta for use in treating chronic intestinal inflammatory disease

Also Published As

Publication number Publication date
DK1409539T3 (da) 2006-07-31
US7141262B2 (en) 2006-11-28
ES2258154T3 (es) 2006-08-16
FR2827290A1 (fr) 2003-01-17
US20050250697A1 (en) 2005-11-10
EP1409539B1 (de) 2006-03-29
FR2827290B1 (fr) 2004-07-09
US20040097714A1 (en) 2004-05-20
JP2005506316A (ja) 2005-03-03
US20050250698A1 (en) 2005-11-10
JP4688092B2 (ja) 2011-05-25
DE60210304T2 (de) 2006-12-07
CA2434303C (fr) 2013-05-14
NZ529180A (en) 2005-05-27
US8937043B2 (en) 2015-01-20
AU2002329364B8 (en) 2008-12-04
WO2003006500A1 (fr) 2003-01-23
DE60210304D1 (de) 2006-05-18
GB0324873D0 (en) 2003-11-26
CA2434303A1 (fr) 2003-01-23
EP1409539A1 (de) 2004-04-21
AU2002329364B2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
DE60210304D1 (de) Verfahren zur herstellung einer proteinhaltigen fraktion, mit beta-tgf in aktivierter form bereichert, sowie die so erhaltene fraktion und deren therapeutische verwendungen
ATE376362T1 (de) Verfahren zur herstellung eines lactosefreien milchprodukts
NZ585594A (en) Methods for casein production
Butylina et al. Fractionation of whey-derived peptides using a combination of ultrafiltration and nanofiltration
KR101645957B1 (ko) 분비 면역글로블린이 풍부한 우유 분획 제조방법
BR9915573A (pt) Processo de preparação de uma composição protéica e uma fórmula infantil contendo a mesma
DE602005021485D1 (de) Verfahren und zusammensetzungen mit molkeproteinisolaten
MX381074B (es) Composiciones funcionales derivadas de frijol mungo.
CA2259761A1 (en) A continuous process of dynamic high-pressure homogenization for the denaturation of proteins
RU2013142354A (ru) Сыр и его получение
EA200000049A1 (ru) Способ производства стерильного обезжиренного молока
BRPI0603380A (pt) método para preparar material de proteìna do soro de leite desflavorizado, e, produto alimentìcio contendo soro de leite
ATE364322T1 (de) Verfahren zur herstellung eines beta- laktoglobulin-angereichertes molkenproteinkonzentrates und darauf basierender texturverstärker zur verwendung in milchprodukten
CY1107082T1 (el) Μεθοδος καθαρισμου αλβουμινης η οποια περιλαμβανει ενα σταδιο νανοδιηθησης, διαλυμα και συνθεση για θεραπευτικη χρηση που περιεχουν την ιδια
DE502004004681D1 (de) Verfahren zur herstellung von salzen schwach koordinierender aniomen, derartige salze sowie deren verwendung
DE602004025248D1 (de) Verfahren zur herstellung eines konzentrierten milchproteinbestandteils
AU2017311557B2 (en) Process for producing infant formula products and dairy products
MX2009006717A (es) Procedimiento para el tratamiento de un flujo de materiales.
ATE465998T1 (de) Verfahren zur herstellung und reinigung von 1,7'- dimethyl-2'-propyl-2,5'-bi-1h-benzimidazol
ATE247628T1 (de) Verfahren zur herstellung von gabapentin
MX2007003149A (es) Metodo para desaborizar materiales derivados de soja usando electrodialisis.
DE50214894D1 (de) Verfahren zur herstellung von oxirancarbonsäuren und derivaten davon
JP2000281639A (ja) 乳由来の尿素含有組成物及びその製造法
JP5546718B2 (ja) ラクトシルセラミド組成物及びその製造方法
DE69425353D1 (de) Verfahren zur Rückgewinnung von Rohstoffen bei der Herstellung von Aspartam

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1409539

Country of ref document: EP